Key facts
- This page summarizes Ann M. Hanly's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Feb 2024, 19:34.
Ann M. Hanly - 22 Feb 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)
- Reporting relationship
- EVP & Chief Technology Officer
- Issuer ticker
- VIR
- Reported as of
- 22 Feb 2024
- Net transaction value
- -$123,521
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2024, 19:34:07 UTC
- Prior SEC filing
- 31 Mar 2023
- Next SEC filing
- 02 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sung Lee, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ann M. Hanly filed Form 4 for Vir Biotechnology, Inc. (VIR) on 26 Feb 2024.
Change
- Previous filing in this sequence was filed on 31 Mar 2023.
- Current net transaction value: -$123,521.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +32,500
- Change %
- +28%
- Price
- $0.000000
- Shares after
- 147,076
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
VIR
transaction
Common Stock
Sale
- Transaction value
- $123,521
- Shares
- -12,296
- Change %
- -8.4%
- Price
- $10.05
- Shares after
- 134,780
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
VIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12
- Date
- 22 Feb 2024
- Ownership
- See footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +65,000
- Change %
- Price
- $0.000000
- Shares after
- 65,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,000
- Exercise price
- $10.11
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
Footnote F2
Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Footnote F3
The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
Footnote F4
25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.